$PRAX

UBS initiated coverage on Praxis Precision Medicine (PRAX) with a 'Buy' rating and a $706 price target. The company's current price is $248.24, which is significantly higher than its GF Value of $11.67, indicating a 2027.2% overvaluation. PRAX has a GF Score of 40, reflecting concerns about its financial health and growth potential. The company is a clinical-stage biopharmaceutical firm focusing on central nervous system disorders.

HC Wainwright & Co. reiterated a Buy rating on Praxis Precision Medicine with a $1201 price target, implying a 402.5% upside from the Oct 14 close. The target is based on positive clinical data for ulixacaltamide in essential tremor and strong valuation metrics, reflecting high success probabilities for the company's pipeline assets.

Needham & Company identified five biotech stocks as top picks for the second half of 2026, all with Buy ratings. Key catalysts include clinical data readouts for Praxia Therapeutics (PRAX), Acadia Pharmaceuticals (ACAD), Biogen (BIIB), Axsome Therapeutics (AXSM), and Alkermes (ALKS). Price targets and analyst upgrades were also noted for these companies.

Praxis Precision Medicines (PRAX) reported Q2 2026 results on an earnings call. Cash and marketable securities rose to $1.4B at June 30, 2026. Q2 net loss was $83.7M, with $78M operating cash burn. Ulixacaltamide PDUFA is Jan. 29, 2027, relutrigine PDUFA Dec. 27, 2026. The POWER1 vormatrigine trial missed its primary endpoint.

Praxis Precision Medicines (PRAX) says it is entering a key period with four late-stage assets and FDA Breakthrough Therapy Designations. Two candidates are under FDA review: Relutrigine (priority review, decision Dec 27, 2026) and Ulixacaltamide (decision Jan 29, 2027). Relutrigine peak DEE revenues are projected over $5B, Ulixacaltamide over $10B. Vormatrigine Phase 2/3 POWER1 missed a primary endpoint; POWER2 enrollment was paused and plans to restart are underway.

Praxis Precision Medicines (PRAX) shares rose 9.3% pre-open after the company reported Q2 2026 results and said the FDA completed mid-cycle reviews for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (PDUFA Dec 27, 2026) with no major safety or efficacy concerns and no advisory committee. FDA inspections had no Form 483 observations. Praxis reported about $1.4B cash and investments as of June 30, 2026 and received a third Breakthrough Therapy Designation for elsunersen.

Praxis Precision Medicines, Inc. (PRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA

Praxis Precision Medicines (NASDAQ:PRAX) and Remagine Labs announced a licensing and research collaboration to develop an iontophoretic transdermal patch delivering ulixacaltamide, using Remagine’s multi-day skin dosing platform. Separately, Praxis said the FDA extended a relutrigine NDA review by three months, moving the PDUFA date from Sept. 27 to Dec. 27.

Praxis Precision Medicines (NASDAQ: PRAX) and Remagine Labs announced a research and license collaboration to develop an iontophoretic transdermal patch delivering ulixacaltamide for essential tremor. The FDA accepted Praxis’s NDA in April 2026 with a PDUFA target date of Jan. 29, 2027. Praxis will invest in Remagine’s equity to accelerate the program.

DeSimone Jill sold 11,600 shares of Praxis Precision Medicines, Inc. (PRAX) at an average of $311.32 ($301.44–$315.70, $3.61M total) across 12 trades on 2026-06-24 under a Rule 10b5-1 trading plan.